TerminatedPhase 1Phase 2

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

NCT03601897

What is this trial?

Generating plain-language summary...

Generating eligibility summary...

Summarizing study design...

Primary location

University of Alabama Comprehensive Cancer Center

Birmingham, Alabama, United States

+13 additional locations

Save this trial

University of Alabama Comprehensive Cancer CenterBirmingham, Alabama, United States
University of Colorado Denver- Anschutz Medical CenterAurora, Colorado, United States
Northwestern University Feinberg School of MedicineChicago, Illinois, United States
The University of Kansas Clinical Research CenterKansas City, Kansas, United States
Dana-FarberBoston, Massachusetts, United States
Northwell Health/Monter Cancer CenterLake Success, New York, United States
Montefiore Medical CenterThe Bronx, New York, United States
Ohio State University Wexner Medical CenterColumbus, Ohio, United States
University of Oklahoma Health Sciences CenterOklahoma City, Oklahoma, United States
Fox Chase Cancer CenterPhiladelphia, Pennsylvania, United States
Women & Infants HospitalProvidence, Rhode Island, United States
Sarah Cannon Research InstituteNashville, Tennessee, United States
MD Anderson Cancer CenterHouston, Texas, United States
Oncology Consultants- Texas Medical CenterHouston, Texas, United States